Domestic Urological Drainage Products News – May 2026

May 2026 witnessed profound market transformation and technological innovation in China’s urological drainage product sector. The most significant industry development this month centered on the nationwide implementation of the selection results from the sixth round of national centralized high-value medical consumables procurement (volume-based procurement, VBP), which brought historic price reductions for urological interventional consumables. Concurrently, leading domestic companies continued to make strides in technological innovation and intellectual property, with several core patents and innovative products gaining approval, injecting new momentum into the industry’s transition from pure price competition to a focus on “quality and innovation.”

Below is a summary of key news in the domestic urological drainage product sector for May 2026.

Centralized Procurement Rollout: Urological Interventional Consumables Enter a New Era of Affordable Pricing

The most important milestone in the urological drainage sector this month was the nationwide implementation of the selection results of the sixth round of national centralized high-value medical consumables procurement across multiple provinces including Inner Mongolia, Jilin, Ningxia, Anhui, Shanghai, Guangdong, and Chongqing in May 2026. This marks the first time that urological interventional consumables have been officially included in a national-level centralized procurement, signaling a fundamental price restructuring for a market long exempt from such measures.

Official data indicates that this round covered 12 product categories across drug-coated balloons and urological interventions, with 440 products from 202 companies selected, a selection rate of nearly 89%. Among these, the selected prices for urological interventional consumables (including nephrostomy kits, Ureteral Stents, guidewires, and other key drainage components) dropped significantly, ranging from RMB 60 to 1,537. The procurement period for this round is uniformly set until December 31, 2028, meaning the market pricing system for urological consumables will operate at these new, lower levels for the next three years.

With implementation notices issued across various provinces and cities, the financial burden on patients with urological disorders will be notably reduced. Meanwhile, both foreign brands such as B. Braun and Boston Scientific, and domestic companies such as Xinguangwei Medical and Tuoren Group, are engaging in intense competition for market share, which will further accelerate the domestic substitution and standardized development of the Chinese urological consumables market.

Innovation Momentum: Patent Achievements, New Product Approvals, and Updated Standards

Despite significant pricing pressures from centralized procurement, the pace of innovation in the domestic urological drainage sector did not wane. Several companies announced important product approvals and technological breakthroughs during May.

Product approvals: In late May, Hainan Maiwei Medical and Tuoren Group reported major regulatory successes. According to announcements from the Hainan Medical Products Administration, Tuoren Group’s Hainan Medical Device subsidiary received multiple registrations in April, including the “sterile single-use urinary catheter and accessories,” “sterile single-use super-slippery urinary catheterization kit,” and “sterile single-use negative pressure drainage device,” further enriching its portfolio of advanced consumables in urology and wound management.

Patent innovations: Victor Medical, a leading domestic urological consumables manufacturer, obtained a design patent for its “pen-style intermittent urinary catheter,” designed to help patients with dysuria or bladder dysfunction empty their bladders regularly. The product’s compact and portable design reflects a trend toward user-friendly and portable catheter products. Additionally, Micro-Tech (Nanjing) Co., Ltd., a major player in minimally invasive instruments, successfully obtained a utility model patent in early May for a “drainage tube delivery device and endoscopic equipment.” This patented technology integrates electrode components with the drainage tube body, enabling combined intraoperative channel establishment and drainage tube placement. It avoids tissue fluid leakage and positioning errors caused by instrument exchanges in traditional surgery, significantly improving surgical safety and success rates.

Registration standards: On May 18, the National Medical Products Administration (NMPA) released the list of medical devices approved in April 2026, totaling 318 products. Various regional medical product administration departments also accelerated the approval and online listing processes for clinically essential consumables like drainage tubes and catheters. For example, Guangdong and Liaoning provinces issued announcements in late May regarding new online listings and approved products, including “sterile single-use urinary catheterization kits” and “hydrophilic-coated urinary catheters,” ensuring diverse clinical options post-centralized procurement.

Clinical Need-Driven: Industry-Academia Collaborations Focus on Intelligent Anti-Blocking Solutions and Refined Care

Beyond traditional urinary catheters and stents, May also saw several high-value scientific and technological achievements aimed at addressing specific clinical pain points.

On May 26, an innovative result from Tongji Hospital affiliated with Huazhong University of Science and Technology attracted widespread attention. Aimed at the common clinical problem of drainage tube blockage, the invention of a “negative pressure-controlled urine drainage system and method” was publicly unveiled. This technology uses intelligent monitoring equipment to periodically clear urine retained in the bladder or drainage tube, enabling more accurate calculation of true urine volume and providing reliable monitoring data for acute kidney injury (AKI), while significantly reducing the risk of tube blockage and urinary tract infection.

Additionally, at the clinical care level, a utility model patent for a “fixation structure for medical drainage tubes” was officially authorized on May 8. This fixation structure, designed with a collar and cushion pad, effectively addresses displacement issues of indwelling drainage tubes in clinical settings, reducing the risk of dislodgement due to tube traction and associated pressure ulcers, signifying a move toward refined, comfort-oriented basic clinical care consumables.

Market Outlook and Summary

Overall, May 2026 represents a critical inflection point for China’s urological drainage product industry. The implementation of national centralized procurement accomplished the “first round of price rationalization” in this field. Concurrently, sustained innovation by research institutions and leading companies demonstrates that the industry is not stagnating due to price reductions. As the benefits of regional centralized procurement policies are released, companies with cost control capabilities, technological innovation strengths, and comprehensive industry chain layouts will be better positioned. In the future, the core competitiveness of domestic urological drainage products will shift from simple channel and price competition to a comprehensive contest of “innovative technology + precise clinical solutions + total lifecycle cost control.”

Disclaimer:
This article only provides information and trend analysis of the medical consumables industry for industry reference and exchange only. It does not constitute any investment, medical diagnosis and treatment, or business decision-making advice.
Relevant policies and data are sourced from public information; please refer to official authoritative releases for specifics. All accompanying images are for scene illustration only, without any brand endorsement or commercial promotion implication.
All professional medical operations and the use of medical consumables shall comply with hospital clinical standards and professional medical guidance.